Michael Gelband’s Axsome Therapeutics AXSM Stock Holding History

Michael Gelband’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,763	Closed	-$3M	–	1575
2026 Q1	$3M	Buy	+17,763	New	+$3.07M	0.02%	619
2025 Q2	–	Sell	-52,683	Closed	-$6.14M	–	1466
2025 Q1	$6.14M	Buy	+52,683	New	+$6M	0.06%	348
2024 Q4	–	Sell	-29,479	Closed	-$2.65M	–	1524
2024 Q3	$2.65M	Buy	+29,479	New	+$2.57M	0.02%	619
2023 Q2	–	Sell	-96,684	Closed	-$5.96M	–	1846
2023 Q1	$5.96M	Buy	+96,684	New	+$6.35M	0.05%	455
2022 Q4	–	Sell	-5,444	Closed	-$243K	–	1632
2022 Q3	$243K	Buy	+5,444	New	+$272K	﹤0.01%	1579
2022 Q2	–	Sell	-11,627	Closed	-$481K	–	1927
2022 Q1	$481K	Buy	+11,627	New	+$360K	0.01%	1560
2020 Q3	–	Sell	-36,804	Closed	-$3.03M	–	1740
2020 Q2	$3.03M	Buy	+36,804	New	+$2.83M	0.08%	290
2019 Q3	–	Sell	-21,703	Closed	-$559K	–	1329
2019 Q2	$559K	Sell	21,703 -41,069	-65%	-$823K	0.02%	418
2019 Q1	$893K	Buy	+62,772	New	+$583K	0.07%	208

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Michael Gelband's AXSM Position: Q2 2026 in Review

Michael Gelband sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 17,763 shares — an estimated $3M sold.

Michael Gelband first reported a position in AXSM in Q1 2019 and held it in 9 quarters. The position peaked at $6.14M in Q1 2025. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Michael Gelband reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 17,763 Axsome Therapeutics shares in Q2 2026, an estimated $3M.
Michael Gelband first reported a position in Axsome Therapeutics in Q1 2019 and held it in 9 quarters.
Michael Gelband's Axsome Therapeutics position peaked at $6.14M in Q1 2025.
502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.